02/28/2026
BIG CHANGES are coming to Indiana on July 1, 2026.
New legislation (SB 282) will reshape how peptide therapies are prescribed and dispensed โ bringing clearer standards, stronger oversight, and improved patient safety.
At the same time, there is encouraging regulatory progress at the federal level. Several peptides that were previously listed in Category 2 (safety concerns) have been removed and are now under review. If these substances are ultimately placed into Category 1, they may become eligible for compounding through licensed pharmacies.
This shift could move peptide therapies out of the research-only gray market and into regulated compounding channels โ improving safety, quality, and patient confidence.
โ Enhanced pharmacy oversight & sourcing standards
โ Increased transparency & regulatory clarity
โ Potential expansion of access through legitimate compounding
โ Safer options for patients seeking innovative therapies
Peptide therapies are being studied for their potential to support:
โข tissue repair & recovery
โข immune system function
โข metabolic health
โข inflammation balance
โข skin & hair rejuvenation
โข overall wellness & longevity support
As guidance evolves, our priority remains providing care that is safe, compliant, and evidence-guided while helping patients access emerging therapies responsibly.
We are actively monitoring these changes and will continue to share updates as regulations are finalized.
Have questions about peptide therapy and whether it may be right for you? Weโre here to help.
๐ฑ 574-622-1522
๐ npswellness.com
๐ 5230 Beck Dr, Ste 3, Elkhart, IN
